Fig. 1 · Structure

Documents & Downloads

Apalutamide (ARN-509)

Cat. No. A11923 CAS 956104-40-8

Androgen Receptor inhibitor

ARN-509 is an androgen receptor antagonist with potential antineoplastic activity. ARN-509 binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes.

In Stock

Publications for Apalutamide

1 publication citing this product

  1. Frédérique Mittler, .et al. , Front Oncol, 2017, 7: 293 PMID: 29322028

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Apalutamide (ARN-509) competes with androgen binding to AR. In LNCaP/AR(cs) whole cells, its 18F-FDHT displacement IC50 was 16.0 ± 2.1 nM (mean ± SEM, five replicate experiments). The apparent advantage over bicalutamide was assay-dependent and was not reproduced in the cell-extract assay described by the authors. [1]

AR genotype can change the functional response to ARN-509. In an LNCaP EGFP reporter model, 10 μM ARN-509 for four days suppressed wild-type AR reporter activity but increased activity with AR F876L. Antagonism should therefore not be generalized across AR mutants. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Androgen Receptor (Cell-free assay) 16 nM
GABAA receptor (Cell-free assay) 3 μM

Cellular Effect

Cell Line Activity Value Description Reference
HEK293 IC50 0.016 μM Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay [PMID: 30525603]
LNCaP IC50 174 nM Antiproliferative activity against human LNCAP cells after 3 days [PMID: 26046313]

In Vitro Studies

ARN-509 produced endpoint- and model-dependent responses in prostate cancer spheroids. The reported area EC50 was 80 nM in VCaP after four days and 13 nM in LNCaP after two days. VCaP ATP EC50 values were 100 nM in spheroids and 150 nM in monolayers; LNCaP ATP EC50 entries were n/a. The authors interpreted ARN-509 responses as mostly cytostatic. LNCaP CellEvent signal decreased, so these results do not establish uniform apoptosis induction. [3]

Whole-cell competition for androgen receptor binding

Cell-based study · LNCaP/AR(cs) prostate cancer cells with increased AR expression [1]

ARN-509 displaced 18F-FDHT in intact cells. Its apparent potency advantage over bicalutamide was assay-dependent: the authors report no corresponding separation in MDA-MB-453 cell extracts. This is a ligand-displacement IC50, not a treatment concentration or dissociation constant.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Displacement of 18F-FDHT from AR in whole cellsIC50 16.0 ± 2.1 nM (mean ± SEM, five replicate experiments)[1]
Bicalutamide comparator in the same whole-cell binding assayIC50 160 ± 29 nM (mean ± SEM, five replicate experiments)[1]

Literature-Reported Treatment Conditions

Method
Concentration-response competition against 18F-FDHT in intact LNCaP/AR(cs) cells.
Reported limits
Binding incubation time and vehicle are not specified in the read main-text methods/caption; detailed supplemental methods were not retrieved. No conditions were borrowed from another paper.
Methods and source locations

Compound reported in the paper: Apalutamide; Compound label in the paper: ARN-509

Reported research material and model only; no salt conversion or validation of a current Adooq lot.

Figure 1A–B and caption; Results, first AR-binding paragraph; Materials and Methods, ligand-binding studies

Displacement of 18F-FDHT from AR in whole cells: Whole-cell radioligand competition. Figure 1B representative curve uses n=3 with SD error bars; inset summarizes five replicate experiments. — Figure 1B inset and caption

Bicalutamide comparator in the same whole-cell binding assay: Same Figure 1B assay; FDHT and MDV3100 also included as competitors. — Figure 1B inset and caption

Multi-endpoint ARN-509 response in prostate cancer spheroids

Cell-based study · VCaP and LNCaP spheroids with matched monolayer ATP comparisons; VCaP 4-day and LNCaP 2-day treatment [3]

Spheroid area and LysoTracker signals changed at lower concentrations in LNCaP than VCaP. VCaP had a reported ATP EC50, whereas LNCaP ATP EC50 entries were n/a. CellEvent signal increased in VCaP but decreased in LNCaP. The authors tentatively classified ARN-509 responses in both models as mostly cytostatic. Endpoint-specific EC50 values do not establish equivalent cell killing.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Reduction of projected spheroid areaEC50 VCaP: 80 nM; LNCaP: 13 nM[3]
CellEvent caspase-3/7 fluorescence responseEC50 VCaP: 400 nM (increasing signal); LNCaP: 15 nM (decreasing signal)[3]
Change in spheroid-associated LysoTracker signalEC50 VCaP: 100 nM; LNCaP: 13 nM[3]
ATP endpoint response in 3D and 2D culturesEC50 VCaP: 3D 100 nM, 2D 150 nM; LNCaP: 3D n/a, 2D n/a[3]
Shape P2A spheroid integrity responseEC50 availability VCaP: n/a; LNCaP: n/a[3]

Literature-Reported Treatment Conditions

Treatment concentration
0, 5, 10, 25, 50, 100, 250, 500, 1000 and 5000 nM (Supplementary Table S1)
Exposure duration
VCaP: 4 days; LNCaP: 2 days
Method
Preformed spheroids; high-content area, Shape P2A, CellEvent and LysoTracker measurements, followed by ViaLight ATP assay. Monolayers were compared by ATP assay.
Vehicle
DMSO; shared protocol uses DMSO vehicle controls and limits spheroid-medium DMSO to ≤0.5%.
Reported limits
Endpoint EC50 estimates have no uncertainty intervals in Table 4. Six spheroids/replicates per condition per plate are described in the shared protocol/captions; three replicate plates per experiment are described, but independent biological replicate n for each ARN-509 estimate is not established. LNCaP ATP and Shape P2A EC50 entries are n/a, not zero.
Methods and source locations

Compound reported in the paper: Apalutamide; Compound label in the paper: ARN-509

Reported research material and model only; no salt conversion or validation of a current Adooq lot.

Materials, ARN-509 entry; Methods, shared spheroid treatment/imaging and ATP assays, Monitoring the Effect of Chemotherapy Drugs; Table 4, ARN-509 rows and footnotes; Results, chemotherapy drugs; Supplementary Table S1 and Figures S4, S6

Reduction of projected spheroid area: Author-estimated EC50 values from dose-response curves; endpoint is morphology, not a viability IC50. — Table 4, Area column, ARN-509 rows; Supplementary Figure S4

CellEvent caspase-3/7 fluorescence response: Author-estimated half-change concentration; directions checked in Supplementary Figure S4. — Table 4, 3D-CE column, ARN-509 rows; Supplementary Figure S4

Change in spheroid-associated LysoTracker signal: Author-estimated half-change in fluorescence; not proof of a particular death pathway. — Table 4, LysoT column, ARN-509 rows; Supplementary Figure S4

ATP endpoint response in 3D and 2D cultures: ViaLight ATP assay; author estimates in Table 4. LNCaP retains substantial ATP across the tested range in Figure S6. n/a is retained without inventing a value. — Table 4, 3D-ATP and 2D-ATP columns; Supplementary Figure S6

Shape P2A spheroid integrity response: Table 4 entries retained; no EC50 assigned. — Table 4, Shape P2A column, ARN-509 rows

AR genotype reverses ARN-509 reporter response

Cell-based study · LNCaP-Pb.PSE.EGFP reporter cells ectopically expressing wild-type AR or AR F876L (paper nomenclature) [2]

After four days, 10 μM ARN-509 reduced EGFP reporter fluorescence in wild-type AR cells but increased it in AR F876L cells. This is a genotype-dependent transcriptional reporter result, not a cell-survival assay or a clinical resistance frequency.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Geometric-mean EGFP fluorescence, wild-type ARGeometric mean FL1-H Vehicle: 432; 10 μM ARN-509: 84.6[2]
Geometric-mean EGFP fluorescence, AR F876LGeometric mean FL1-H Vehicle: 331; 10 μM ARN-509: 1279[2]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM ARN-509
Exposure duration
4 days
Method
EGFP reporter flow cytometry with matched vehicle controls for each AR genotype.
Vehicle
DMSO; drug serial dilutions in DMSO described in Materials.
Reported limits
Replicate n and uncertainty are not specified for the Figure 2 supplement 4 geometric-mean table. No statistical significance or population resistance frequency inferred.
Methods and source locations

Compound reported in the paper: Apalutamide; Compound label in the paper: ARN-509

Reported research material and model only; no salt conversion or validation of a current Adooq lot.

Figure 2—figure supplement 4 and caption; functional-validation Results; Materials and cell lines; Flow cytometry analysis

Geometric-mean EGFP fluorescence, wild-type AR: Flow cytometry FL1-H; values transcribed from embedded table, not estimated from histogram. — Figure 2—figure supplement 4 embedded table

Geometric-mean EGFP fluorescence, AR F876L: Same flow-cytometric reporter design, mutant-genotype arm. — Figure 2—figure supplement 4 embedded table

In Vivo Studies

In castrate male mice bearing LNCaP/AR(cs) xenografts, daily oral ARN-509 at 10 mg/kg/day for 28 days produced >50% volume regression in 8/10 tumors, including two that became nonpalpable. The corresponding count was 1/10 with bicalutamide at the same dose; 7/9 vehicle-treated tumors grew. These are tumor-level results from this model. [1]

Regression of LNCaP/AR(cs) xenografts after 28 days

Animal study · Castrate male mice bearing LNCaP/AR(cs) xenografts; mean starting tumor volume 200 mm³ [1]

Daily oral ARN-509 at 10 mg/kg/day produced >50% tumor-volume regression in 8/10 tumors, compared with 1/10 on bicalutamide. Seven of nine vehicle-treated tumors grew. Two ARN-509-treated tumors were no longer palpable. Counts refer to tumors as reported, not independently verified animal numbers.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumors with >50% volume regression at day 28Tumor count ARN-509: 8/10; bicalutamide: 1/10[1]
Between-group comparison of tumor-volume responsep value Vehicle vs ARN-509: p=0.0001; vehicle vs bicalutamide: p=0.004; ARN-509 vs bicalutamide: p=0.002[1]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Daily
Treatment course
28 days
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
ARN-509
10 mg/kg/day
Vehicle; bicalutamide 10 mg/kg/day8/10 tumors regressed >50%; two became nonpalpable.[1]
VehicleARN-509 and bicalutamide arms7/9 tumors increased in volume.[1]
Bicalutamide
10 mg/kg/day
Vehicle; ARN-509 10 mg/kg/day1/10 tumors regressed >50%.[1]
ARN-509
Model: Castrate male mice bearing LNCaP/AR(cs) xenografts; mean starting tumor volume 200 mm³
Reported limits: Vehicle composition and unique animal counts are not established from the read main-text sources.
Vehicle
Model: Castrate male mice bearing LNCaP/AR(cs) xenografts; mean starting tumor volume 200 mm³
Reported limits: Vehicle composition and unique animal counts are not established from the read main-text sources.
Bicalutamide
Model: Castrate male mice bearing LNCaP/AR(cs) xenografts; mean starting tumor volume 200 mm³
Reported limits: Vehicle composition and unique animal counts are not established from the read main-text sources.
Methods and source locations

Compound reported in the paper: Apalutamide; Compound label in the paper: ARN-509

Reported research material and model only; no salt conversion or validation of a current Adooq lot.

Figure 3B and caption; Results, therapeutic-effect paragraph; Materials and Methods, animal studies

Tumors with >50% volume regression at day 28: Individual tumor-volume change from baseline. — Figure 3B; Results, therapeutic-effect paragraph

Between-group comparison of tumor-volume response: Unpaired t-test as reported in Figure 3B caption. — Figure 3B caption

ARN-509 · Figure 3B and caption; Results, therapeutic-effect paragraph

Vehicle · Figure 3B and caption; Results, therapeutic-effect paragraph

Bicalutamide · Figure 3B and caption; Results, therapeutic-effect paragraph

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 956104-40-8
Applications Androgen Receptor inhibitor
Formula C21H15F4N5O2S
Molecular Weight 477.4
Synonyms ARN509
SMILES
CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CN=C(C(=C4)C(F)(F)F)C#N)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 18 mg/mL (37.7 mM)
Water Insoluble
Ethanol 5 mg/mL (10.47 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
2 mg/mL
Vehicle
2% DMSO+40% PEG 300+2% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer research (2012). PMID: 22266222 DOI: 10.1158/0008-5472.can-11-3948 Source material
  2. [2] Balbas MD, Evans MJ, Hosfield DJ, et al. Overcoming mutation-based resistance to antiandrogens with rational drug design. eLife (2013). PMID: 23580326 DOI: 10.7554/elife.00499 Source material
  3. [3] Mittler F, Obeïd P, Rulina AV, et al. High-Content Monitoring of Drug Effects in a 3D Spheroid Model. Frontiers in oncology (2017). PMID: 29322028 DOI: 10.3389/fonc.2017.00293 Source material

Publications

1 publication citing this product

  1. Frédérique Mittler, .et al. , Front Oncol, 2017, 7: 293 PMID: 29322028

Added to your cart

View Cart Checkout
Loading...